Haworth Kellie B, Leddon Jennifer L, Chen Chun-Yu, Horwitz Edwin M, Mackall Crystal L, Cripe Timothy P
Division of Hematology/Oncology/Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio.
Pediatr Blood Cancer. 2015 Apr;62(4):571-6. doi: 10.1002/pbc.25359. Epub 2014 Dec 18.
After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.
经过数十年未实现的承诺，癌症免疫疗法已达到一个转折点，目前有几种获得美国食品药品监督管理局（FDA）批准的产品上市，还有更多产品在成人和儿科临床试验中显示出前景。肿瘤细胞I类主要组织相容性复合体（MHC）的表达已成为许多免疫疗法治疗成功的潜在决定因素。在此，我们综述了有关儿科癌症中MHC I类表达的现有知识，包括对预后意义的讨论、MHC对T细胞与自然杀伤（NK）细胞介导疗法的相反影响，以及逆转或规避MHC下调的策略。
